Sep 24, 2024 8:00 am EDT Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Sep 23, 2024 9:25 am EDT Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
Sep 17, 2024 9:15 am EDT Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Sep 06, 2024 8:30 am EDT Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
Aug 07, 2024 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jul 31, 2024 9:00 am EDT Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7
Jun 28, 2024 9:00 am EDT Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
Jun 25, 2024 8:30 am EDT Capricor Therapeutics Announces Pre-BLA Meeting with FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Jun 11, 2024 9:25 am EDT Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway